{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:27:38Z","timestamp":1793755658570,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Optimal treatment for synchronous brain metastases at lung cancer diagnosis depends on subtype, but histologic\/molecular profiling is often delayed. We developed machine-learning models using clinical and imaging data to classify lung cancer into three subtypes with distinct brain metastasis treatment implications: small cell lung cancer (SCLC), EGFR-mutated non-small cell lung cancer (EGFR+), and EGFR\u2013wild-type non-small cell lung cancer (EGFR-).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively identified patients with metastatic lung cancer diagnosed from 2016 to 2025 at a single institution. Patients without brain metastases at diagnosis formed the training cohort, while patients presenting with synchronous brain metastases formed the testing cohort. Clinical variables and thoracic imaging features from diagnostic chest CT reports were used to train LASSO logistic regression and random forest models, evaluated via AUC and standard diagnostic metrics. Feature contributions were assessed using logistic regression coefficients and random forest permutation importance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 305 patients, 182 were used for training and 123 comprised the testing cohort. Logistic regression achieved AUCs of 0.887, 0.811, and 0.801 for EGFR+, SCLC, and EGFR-, respectively; random forest achieved 0.907, 0.783, and 0.810. Adding imaging features to clinical variables improved prediction for EGFR\u2009+\u2009and SCLC. Contributory imaging features included fibrosis, emphysema, miliary pattern, cavitation, pleural attachment, and vessel encasement, among others. Three-way prediction showed highest positive predictive value for EGFR\u2009+\u2009and high negative predictive value for SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combined clinical and chest imaging features can help predict lung cancer subtype, supporting early multidisciplinary discussions for patients with synchronous brain metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05812-z","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:23:12Z","timestamp":1791202992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive modeling of lung cancer subtype with integration of clinical and thoracic imaging features to guide early brain metastasis management"],"prefix":"10.1007","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-3880","authenticated-orcid":false,"given":"Jino","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Buclez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lubisich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Hanubal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Inda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caressa","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"1","key":"5812_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J (2021) Small-cell lung cancer. Nat Rev Dis Primers 7(1):3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"5812_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa071780","volume":"357","author":"B Slotman","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357(7):664\u2013672. https:\/\/doi.org\/10.1056\/NEJMoa071780","journal-title":"N Engl J Med"},{"issue":"5","key":"5812_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","volume":"18","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Yamanaka T, Seto T et al (2017) Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18(5):663\u2013671. https:\/\/doi.org\/10.1016\/S1470-2045(17)30230-9","journal-title":"Lancet Oncol"},{"issue":"27","key":"5812_CR4","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1200\/JCO-25-00056","volume":"43","author":"AA Aizer","year":"2025","unstructured":"Aizer AA, Tanguturi SK, Shi DD et al (2025) Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1\u201310 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial. J Clin Oncol 43(27):2986\u20132997. https:\/\/doi.org\/10.1200\/JCO-25-00056","journal-title":"J Clin Oncol"},{"issue":"8","key":"5812_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049\u20131060. https:\/\/doi.org\/10.1016\/S1470-2045(17)30441-2","journal-title":"Lancet Oncol"},{"issue":"8","key":"5812_CR6","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","volume":"18","author":"A Mahajan","year":"2017","unstructured":"Mahajan A, Ahmed S, McAleer MF et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040\u20131048. https:\/\/doi.org\/10.1016\/S1470-2045(17)30414-X","journal-title":"Lancet Oncol"},{"key":"5812_CR7","doi-asserted-by":"publisher","first-page":"JCO2018786186","DOI":"10.1200\/JCO.2018.78.6186","volume":"20","author":"T Kayama","year":"2018","unstructured":"Kayama T, Sato S, Sakurada K et al (2018) Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol Published online June 20:JCO2018786186. https:\/\/doi.org\/10.1200\/JCO.2018.78.6186","journal-title":"J Clin Oncol Published online June"},{"key":"5812_CR8","doi-asserted-by":"publisher","first-page":"103549","DOI":"10.1016\/j.jtho.2026.01.001","volume":"12","author":"CK Lee","year":"2026","unstructured":"Lee CK, Lefresne S, Soon YY et al (2026) Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials. J Thorac Oncol Published online January 12:103549. https:\/\/doi.org\/10.1016\/j.jtho.2026.01.001","journal-title":"J Thorac Oncol Published online January"},{"issue":"3","key":"5812_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ijrobp.2019.02.051","volume":"104","author":"E Miyawaki","year":"2019","unstructured":"Miyawaki E, Kenmotsu H, Mori K et al (2019) Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. Int J Radiation Oncology*Biology*Physics 104(3):604\u2013613. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.051","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"10","key":"5812_CR10","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","volume":"35","author":"WJ Magnuson","year":"2017","unstructured":"Magnuson WJ, Lester-Coll NH, Wu AJ et al (2017) Management of Brain Metastases in Tyrosine Kinase Inhibitor\u2013Na\u00efve Epidermal Growth Factor Receptor\u2013Mutant Non\u2013Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. JCO 35(10):1070\u20131077. https:\/\/doi.org\/10.1200\/JCO.2016.69.7144","journal-title":"JCO"},{"issue":"12","key":"5812_CR11","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","volume":"16","author":"H Yamaguchi","year":"2021","unstructured":"Yamaguchi H, Wakuda K, Fukuda M et al (2021) A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603\/WJOG9116L). J Thorac Oncol 16(12):2121\u20132132. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.026","journal-title":"J Thorac Oncol"},{"issue":"7","key":"5812_CR12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.23.02219","volume":"42","author":"PA J\u00e4nne","year":"2024","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K et al (2024) CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor\u2013Mutated Advanced Non\u2013Small-Cell Lung Cancer. JCO 42(7):808\u2013820. https:\/\/doi.org\/10.1200\/JCO.23.02219","journal-title":"JCO"},{"issue":"13","key":"5812_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1001\/jama.2026.0076","volume":"335","author":"AA Aizer","year":"2026","unstructured":"Aizer AA, Shin KY, Catalano PJ et al (2026) Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. JAMA 335(13):1127. https:\/\/doi.org\/10.1001\/jama.2026.0076","journal-title":"JAMA"},{"issue":"15suppl","key":"5812_CR14","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2021.39.15_suppl.9004","volume":"39","author":"NJ Robert","year":"2021","unstructured":"Robert NJ, Nwokeji ED, Espirito JL et al (2021) Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. JCO 39(15suppl):9004\u20139004. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9004","journal-title":"JCO"},{"issue":"3","key":"5812_CR15","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/curroncol31030115","volume":"31","author":"KE Fleming","year":"2024","unstructured":"Fleming KE, Hupel A, Mithoowani H, Lulic-Kuryllo T, Valdes M (2024) Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre. Curr Oncol 31(3):1515\u20131528. https:\/\/doi.org\/10.3390\/curroncol31030115","journal-title":"Curr Oncol"},{"issue":"17","key":"5812_CR16","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JCH Yang","year":"2025","unstructured":"Yang JCH, Lu S, Hayashi H et al (2025) Overall Survival with Amivantamab\u2013Lazertinib in EGFR -Mutated Advanced NSCLC. N Engl J Med 393(17):1681\u20131693. https:\/\/doi.org\/10.1056\/NEJMoa2503001","journal-title":"N Engl J Med"},{"issue":"21","key":"5812_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y et al (2023) Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC. N Engl J Med 389(21):1935\u20131948. https:\/\/doi.org\/10.1056\/NEJMoa2306434","journal-title":"N Engl J Med"},{"issue":"4","key":"5812_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","volume":"12","author":"M Chevallier","year":"2021","unstructured":"Chevallier M, Borgeaud M, Addeo A, Friedlaender A (2021) Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World J Clin Oncol 12(4):217\u2013237. https:\/\/doi.org\/10.5306\/wjco.v12.i4.217","journal-title":"World J Clin Oncol"},{"issue":"33","key":"5812_CR19","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","volume":"36","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC et al (2018) CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non\u2013Small-Cell Lung Cancer. JCO 36(33):3290\u20133297. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118","journal-title":"JCO"},{"issue":"2","key":"5812_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au JSK, Thongprasert S et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2):154\u2013162. https:\/\/doi.org\/10.1097\/JTO.0000000000000033","journal-title":"J Thorac Oncol"},{"issue":"6","key":"5812_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10147-019-01403-3","volume":"24","author":"H Zhang","year":"2019","unstructured":"Zhang H, Cai W, Wang Y, Liao M, Tian S (2019) CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis. Int J Clin Oncol 24(6):649\u2013659. https:\/\/doi.org\/10.1007\/s10147-019-01403-3","journal-title":"Int J Clin Oncol"},{"issue":"47","key":"5812_CR22","doi-asserted-by":"publisher","first-page":"e5426","DOI":"10.1097\/MD.0000000000005426","volume":"95","author":"D Lee","year":"2016","unstructured":"Lee D, Rho JY, Kang S, Yoo KJ, Choi HJ (2016) CT findings of small cell lung carcinoma: Can recognizable features be found? Med (Baltim) 95(47):e5426. https:\/\/doi.org\/10.1097\/MD.0000000000005426","journal-title":"Med (Baltim)"},{"issue":"1","key":"5812_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1148\/radiol.13112553","volume":"268","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Kim YT, Kang CH et al (2013) Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 268(1):254\u2013264. https:\/\/doi.org\/10.1148\/radiol.13112553","journal-title":"Radiology"},{"issue":"4","key":"5812_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/cncr.25618","volume":"117","author":"Y Togashi","year":"2011","unstructured":"Togashi Y, Masago K, Kubo T et al (2011) Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer 117(4):819\u2013825. https:\/\/doi.org\/10.1002\/cncr.25618","journal-title":"Cancer"},{"issue":"1","key":"5812_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1148\/radiol.2016151455","volume":"280","author":"Y Liu","year":"2016","unstructured":"Liu Y, Kim J, Qu F et al (2016) CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma. Radiology 280(1):271\u2013280. https:\/\/doi.org\/10.1148\/radiol.2016151455","journal-title":"Radiology"},{"issue":"2","key":"5812_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1183\/09031936.00006912","volume":"41","author":"SG Wu","year":"2013","unstructured":"Wu SG, Hu FC, Chang YL et al (2013) Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. Eur Respir J 41(2):417\u2013424. https:\/\/doi.org\/10.1183\/09031936.00006912","journal-title":"Eur Respir J"},{"issue":"6","key":"5812_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3892\/mco.2018.1730","volume":"9","author":"A Sekine","year":"2018","unstructured":"Sekine A, Katano T, Oda T et al (2018) Miliary lung metastases from non-small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report. Mol Clin Oncol 9(6):673\u2013676. https:\/\/doi.org\/10.3892\/mco.2018.1730","journal-title":"Mol Clin Oncol"},{"issue":"51","key":"5812_CR28","doi-asserted-by":"publisher","first-page":"e2324","DOI":"10.1097\/MD.0000000000002324","volume":"94","author":"E Miyauchi","year":"2015","unstructured":"Miyauchi E, Motoi N, Ono H et al (2015) Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1. Medicine 94(51):e2324. https:\/\/doi.org\/10.1097\/MD.0000000000002324","journal-title":"Medicine"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05812-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:04:53Z","timestamp":1793754293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05812-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5812"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05812-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10581040\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of University of California Irvine.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the author used Anthropic Claude Sonnet 4.6 for grammar proofreading. Additionally, an institutional, firewalled implementation of Anthropic Claude Sonnet 4.6 was used as part of the study methodology to extract text from deidentified radiology reports using a standardized prompt. The authors reviewed and edited the output as needed and take full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"5"}}